KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Assets Average (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Assets Average for 14 consecutive years, with $571.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 4.12% year-over-year to $571.9 million, compared with a TTM value of $571.9 million through Dec 2025, up 4.12%, and an annual FY2025 reading of $599.7 million, down 13.28% over the prior year.
  • Assets Average was $571.9 million for Q4 2025 at Travere Therapeutics, up from $546.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $803.9 million in Q2 2022 and bottomed at $527.8 million in Q3 2024.
  • Average Assets Average over 5 years is $677.9 million, with a median of $712.8 million recorded in 2022.
  • The sharpest move saw Assets Average increased 20.7% in 2021, then dropped 21.36% in 2024.
  • Year by year, Assets Average stood at $775.9 million in 2021, then decreased by 9.85% to $699.4 million in 2022, then increased by 10.43% to $772.3 million in 2023, then fell by 28.88% to $549.3 million in 2024, then grew by 4.12% to $571.9 million in 2025.
  • Business Quant data shows Assets Average for TVTX at $571.9 million in Q4 2025, $546.9 million in Q3 2025, and $552.1 million in Q2 2025.